Disclosures

Loading...

The speakers of each symposium have been asked to disclose any relationships that could be perceived as a conflict of interest. Disclosures are listed alphabetically by symposium supporter.

Allos Therapeutics, Inc., and Eisai, Inc.

Changing Paradigms in T-cell Lymphomas

  • Francine Foss, MD: research funding from Merck & Co.; paid consultant/advisory board for Allos Therapeutics, Inc. and Merck & Co., Inc.
  • Eric Hsi, MD: research funding from The Cleveland Clinic Foundation; paid consultant/advisory board for Allos Therapeutics, Inc. and Becton, Dickson and Company.
  • Lauren Pinter-Brown, MD: research funding from Jonsson Comprehensive Cancer Center; paid consultant/ advisory board for Allos Therapeutics, Inc., Gloucester Pharmaceuticals, and Millennium Pharmaceuticals, Inc.
  • Andrew Zelenetz, MD, PhD: research funding from Amgen, Genentech, Inc., and GlaxoSmithKline; paid consultant/ advisory board for Celgene Corporation, Cell Therapeutics, Inc., Cephalon, Inc., Genentech, Inc., and GlaxoSmithKline.
  • John Zic, MD: indicated no conflicts of interest.

back to top

Allos Therapeutics, Inc., and Millenium Pharmaceuticals, Inc.

Novel Combinations for Lymphoma: Maximizing the Impact of Targeted Therapies

  • Stephen Smith, MD: indicated no conflicts of interest.
  • Barbara Pro, MD: Allos, Merck, Gloucester, and Rigel and Seattle Genetics.
  • Kieron Dunleavy, MD, PhD: indicated no conflicts of interest.
  • Christian Geisler, MD: indicated no conflicts of interest.
  • Anton Hagenbeek, MD, PhD: Roche International.
  • Christopher R. Flowers, MD: Intellitine, Celgene, Millennium, and Pfizer.

back to top

Amgen, Inc.

The Many New Facets of Immune Thrombocypotenia

  • Drew Provan, MD: consultant for GlaxoSmithKline, Amgen, Inc., and Baxter; non-CME services GlaxoSmithKline and Amgen, Inc.; research support from GlaxoSmithKline.
  • Howard A. Liebman, MD: consultant for Shionogi USA, Inc., and GlaxoSmithKline; and research support from Amgen, Inc., GlaxoSmithKline, Bristol-Myers Squibb, and Immunomedics.
  • Terry Gernsheimer, MD: consultant for Amgen, Inc.; contracted research for GlaxoSmithKline and Amgen, Inc.; research support from GlaxoSmithKline and Amgen, Inc.
  • David J. Kuter, MD, PhD: consultant for Amgen, Inc., GlaxoSmithKline, Ono Pharma USA, and Eisai, Inc.; research support from Amgen, Inc., GlaxoSmithKline, Ono Pharma USA, Eisai, Inc., and Shionogi.
  • Roberto Stasi, MD: consultant for Amgen, Inc. and GlaxoSmithKline.
  • James B. Bussel, MD: consultant for Amgen, Inc., GlaxoSmithKline, Ligand Pharmaceuticals, Shionongi USA, Inc., and Eisai, Inc.

back to top

Aplastic Anemia and MDS International Foundation, Inc.

Myelodysplastic Syndromes: Actively Treating the Disease and Aggressively Supporting the Patient

  • Mikkael Sekeres, MD, MS: Celgene.
  • Jaroslaw Maciejewski, MD, PhD: indicated no conflicts of interest.
  • Eva Hellström-Lindberg, MD, PhD: Celgene.
  • David P. Steensma, MD: BioLumina, Eisai, Genzyme, and Novartis.
  • Aristoteles A.N. Giagounidis, MD, PhD: Amgen, Celgene, and Novartis.
  • Gail Roboz, MD: indicated no conflicts of interest.
  • Alice Houk, MS: indicated no conflicts of interest.

back to top

Bristol-Myers Squibb Company

Practical Approaches to Patient With Chronic Myelogenous Leukemia

  • Neil Shah, MD, PhD: consultant fees from Bristol-Myers Squibb Company and Novartis.
  • Michael Deininger, MD, PhD: research/grant support from Bristol-Myers Squibb Company; honoraria from Ariad Pharmaceuticals, Inc., Calistoga Pharmaceuticals, Inc., and Genzyme Corporation.
  • Jorge E. Cortes, MD: research/grant support and honoraria from Bristol-Myers Squibb Company, Novartis, and Wyeth.
  • Timothy Hughes, MD, MBBS: honoraria from Bristol-Myers Squibb Company and Novartis.
  • Moshe Talpaz, MD: Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Deciphera Pharmaceuticals, LLC, Millennium Pharmaceuticals, Inc., and Novartis; honoraria from Bristol-Myers Squibb Company and Novartis.
  • John M. Goldman, DM: speaker’s bureau for Bristol-Myers Squibb Company and Novartis.

back to top

Celgene Corporation and Therakos, Inc.

State of the Art: B-Cell and T-Cell Lymphoma Management

  • Michael E. Williams, MD: research grant from Celgene Corporation, Cephalon, Genentech BioOncology, Millennium, and Novartis.
  • Randy Gascoyne, MD: indicated no conflicts of interest.
  • Leo I. Gordon, MD: honoraria from Genentech BioOncology; other financial or material support from CureTech.
  • Stephen Ansell, MD, PhD: indicated no conflicts of interest.
  • Craig Moskowitz, MD: grants/research support from Seattle Genetics, Cephalon, Genentech BioOncology, and Eli Lilly and Company.
  • Kerry Savage, MD: honoraria from Allos Therapeutics Corporation, Genentech BioOncology, GlaxoSmithKline, and Cephalon.
  • Jasmine Zain, MD: speaker’s bureau for Allos Therapeutics.

back to top

Celgene Corporation

Real-Life Decisions: An Interactive Case-Based Symposium on the Management of Multiple Myeloma, Myelodysplastic Syndromes, and Acute Myeloid Leukemias

  • William, I. Bensinger, MD: advisory committee for Millennium Pharmaceuticals, Inc., and Onyx Pharmaceuticals, Inc.; consulting agreements with Amgen, Inc., Celgene Corporation, and Genzyme Corporation; paid research for AstraZeneca Pharmaceuticals LP, Facet Biotech Corporation, Genentech BioOncology, Millennium Pharmaceuticals, Inc., and Onyx Pharmaceuticals, Inc.; speakers bureau for Celgene Corporation.
  • Pierre Fenaux, MD, PhD: advisory board for Amgen and Millennium; other financial or material support from Celgene and Millennium.
  • Morie A. Gertz, MD: advisory committee for Celgene Corporation, Eisai, Inc., and Millennium Pharmaceuticals, Inc.
  • Farhad Ravandi, MD: advisory committee for Bayer, Bristol-Myers Squibb, Cephalon, Eisai, Inc., EMD Serono, Genzyme, and Novartis.
  • B. Douglas Smith, MD: consulting agreements from Bristol-Myers Squibb, Celgene, and Novartis; paid research from Eisai, Inc., Infinity Pharmaceuticals, Novartis, and Synta.
  • Ravi Vij, MD: consulting agreements from Onyx; speaker’s bureau for Bristol-Myers Squibb, Celgene, Cephalon, Eisai, Inc., Genzyme, GlaxoSmithKline, and Millennium.

back to top

Cephalon, Inc., Genentech BioOncology/Biogen Idec and Millenium Pharmaceuticals, Inc.

"National NHL Tumor Board:" Clinical Investigators Provide Their Perspectives on Current Cases of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

  • Myron S. Czuczman, MD: advisory committee for Amgen, Inc., Biogen Idec, Celgene Corporation, Cephalon, Inc., Genentech BioOncology, GlaxoSmithKline, Lilly USA, LLC, Millennium Pharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation; lectures for Biogen Idec and Genentech BioOncology.
  • Jonathan W. Friedberg, MD, MMSc: advisory committee for Genentech BioOncology; consulting agreements for Allos Therapeutics, Astellas Pharma US, Inc., Calistoga Pharmaceuticals, Inc., EMD Serono, Inc., and Seattle Genetics; data safety monitoring board for Lilly USA LLC; research support from Cephalon, Inc., and Millennium Pharmaceuticals, Inc.; stock ownership in Bristol-Myers Squibb Company.
  • Stephanie A. Gregory, MD: consultant for Amgen, Inc., Genentech BioOncology, Novartis Pharmaceuticals Corporation, and Spectrum Pharmaceuticals; research support from Celgene Corporation, Curatech Company, Genentech BioOoncology, GlaxoSmithKline, Immunomedics, Inc., and Onyx Pharmaceuticals; speaker’s bureau for Cephalon, Inc., Genentech BioOncology, GlaxoSmithKline, Millennium Pharmaceuticals, Inc., and Spectrum Pharmaceuticals.
  • David G. Maloney, MD, PhD: advisory committee for Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly USA, LLC, Millennium Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc., and Wyeth.
  • Mathias J. Rummel, MD, PhD: advisory committee for Amgen, Inc., Cephalon, Inc., and GlaxoSmithKline.
  • Mitchell R. Smith, MD, PhD: advisory committee for Cephalon Inc. and Wyeth; speaker’s bureau for Allos Therapeutics, Celgene Corporation, Cephalon, Inc., Genentech BioOncology, Millennium Pharmaceuticals, Inc., and Spectrum Pharmaceuticals.

back to top

Esai, Inc.

New Frontiers and Evolving Paradigms in Cancer and Thrombosis: Principles, Challenges, and Solutions

  • Samuel Z. Goldhaber, MD: research support from Bristol-Myers Squibb, Boehringer-Ingelheim, Eisai, Johnson & Johnson, and sanofi-aventis; consultant for Bristol-Myers Squibb and Boehringer-Ingelheim.
  • Frederick R. Rickles, MD: consultant for Eisai, Genmab, and Pharmacyclics; speaker’s bureau for Eisai.
  • Craig Kessler, MD: consultant for Eisai and sanofiaventis; research support from Eisai, sanofi-aventis, and GlaxoSmithKline; stock holder in Ibser.
  • Alok A. Khorana, MD: advisor/consultant and speaker’s bureau for sanofi-aventis and Eisai; research support from sanofi-aventis.
  • Michael Streiff, MD: speaker’s bureau for sanofi-aventis; research support from Bristol-Myers Squibb; honoraria from sanofi-aventis and GlaxoSmithKline.

AML and MDS: Improving Outcomes Through Progress in Biology and Therapy – Clinical Challenges and Interactive Case Presentations

  • Hagop M. Kantarjian, MD: grant/research support from Bristol-Myers Squibb, Cyclacel, Eisai, Genzyme, and Novartis.
  • Jean-Pierre Issa, MD: indicated no conflicts of interest.
  • Gary J. Schiller, MD: grant/research support from Aegera Therapeutics, Antisoma, Celgene, Genzyme, and Millennium Pharmaceuticals, Inc.
  • Judith E. Karp, MD: grant/research support from Genzyme, Merck/Schering, and Sunesis; consultant fees from Antisoma, Genzyme, and Merck/Schering.
  • Harry P. Erba, MD, PhD: consultant fees from Genzyme; grants/research support from Cell Therapeutics, Cephalon, Genzyme, Kanisa, Lilly USA, Novartis, Wyeth, and Xanthus.
  • Eric J. Feldman, MD: indicated no conflicts of interest.
  • Jeffery R. Schriber, MD: indicated no conflicts of interest.

back to top

International Myeloma Foundation

Key Questions for 2010: Latest Developments in Diagnosis, Prognosis, and Treatment of Myeloma

  • Brian G.M. Durie, MD: consulting fees from Celgene and Millennium.
  • Phillippe Moreau, MD: consulting fees from Celgene and Janssen-Cilag.
  • Robert Z. Orlowski, MD, PhD: consulting fees from Celgene, Millennium, and Proteolix.
  • Antonio Palumbo, MD: consulting fees from Celgene and Ortho Biotech.
  • S. Vincent Rajkumar, MD: indicated no conflicts of interest.
  • Jesús F. San Miguel, MD, PhD: consulting fees from Celgene, Millennium, and Ortho Biotech.

back to top

Millenium: The Takeda Oncology Company, Celgene, and Allos Therapeutics

Significance of the Tumor Microenvironment in Hematologic Malignancies

  • Sean Morrison, MD: consulting fees from Hospira; speaker’s bureau for Merck and Pfizer; ownership interests in OncoMed.
  • Louis Staudt, MD, PhD: indicated no conflicts of interest.
  • John DiPersio, MD, PhD: honoria from Genzyme.
  • Irene Ghobrial, MD: consulting fees from Millennium and Genzyme.
  • Iannis Aifantis, PhD: indicated no conflicts of interest.

back to top

Millenium Pharmaceuticals

Challenging Cases in Multiple Myeloma: A Dialogue Between Community and Academic Clinicians to Improve Patient Care and Outcomes

  • Sundar Jaganath, MD: consultant fees from Merck, Millennium, and Celgene.
  • Jonathan Kaufman, MD: consultant fees from Celgene and Millennium.
  • Stefan Knop, MD: honoria from Celgene, Ortho Biotech, and Mundipharma; advisory board for Celgene and Ortho Biotech.
  • Noopur Raje, MD: consultant fees from Celgene and Amgen.
  • G. David Roodman, MD: consultant fees from Amgen, Novartis, Celgene, Acceleron, and Millennium; research support from Novartis.

back to top

Multiple Myeloma Research Foundation

Strategies to Maximize Response Rates and Outcomes in Multiple Myeloma

  • Paul G. Richardson, MD: advisory board/speaker’s bureau for Celgene and Millennium.
  • Sergio Giralt, MD: advisory board/speaker’s bureau for Celgene, Novartis, Genzyme, and Millennium.
  • Meletios Dimopoulos, MD: honoraria from Celgene, Millennium, and Ortho Biotech.
  • Marivi Mateos, MD: speaker’s bureau for Ortho Biotech and Celgene; advisory board for Millennium, Ortho Biotech, and Celgene.

back to top

National Bone Marrow Donor Program

Management of Advanced Non-Hodgkin Lymphomas

  • Ginna Laport, MD, MS: indicated no conflicts of interest.
  • Ajay Gopal, MD: speaker honorarium from Millennium; consulting honorarium from Amgen and Cell Therapeutics, Inc.; and research support from Seattle Genetics, Merck, GlaxoSmithKline, and Cephalon.
  • Philippe Armand, MD: consulting honorarium and research support from Novartis.
  • Julie Vose, MD: research grant support from Allos Therapeutics, Astellas, Bristol-Myers Squibb, Celgene, Genentech, Genzyme, GlaxoSmithKline, Millennium, Novartis, Pharmacyclics, and Rigel.
  • Dennis Confer, MD: indicated no conflicts of interest.

back to top

Novo Nordisk

Management of Elective Surgery in Patients with Hemophilia

  • Christopher A. Ludlam, MB, ChB, PhD: advisory board for Bayer, Baxter, and Wyeth; speaker’s bureau for Wyeth; other financial support from Baxter.
  • Adolpho Llinás, MD: advisory board for Bayer, Johnson & Johnson, and Schering.
  • Mark Reding, MD: advisory board for Bayer and Novo Nordisk Inc.

back to top

Ortho-McNeil Janssen Scientific Affairs, LLC

Defining the Future of Oral Anticoagulant Therapy Across the Spectrum of Thromboembolic Disease

  • Jeffrey I. Weitz, MD: advisory board for Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Portal, sanofi-aventis, Schering-Plough, and SmithKline Beecham; consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Merck AG, Schering-Plough, and The Medicines Company.
  • Richard C. Becker, MD: consultant for Portola Pharmaceuticals, Regado Biosciences, and The Medicines Company; grants from AstraZeneca, Bristol-Myers Squibb/ Sanofi Pharmaceuticals Partnership, Johnson & Johnson, Regado Biosciences, Schering Corporation, and The Medicines Company; honoria from AstraZeneca and Daiichi Sankyo/Eli Lilly.
  • Giancarlo Agnelli, MD: indicated no conflicts of interest.
  • Michael D. Ezekowitz, MD: consultant for ARYx Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Medtronics, Portola, sanofiaventis, and Wyeth.
  • John A. Heit, MD: indicated no conflicts of interest.
  • Kenneth W. Mahaffey, MD: consultant for Adolor Corporation, Alexion, Amgen, Amylin, AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, Bristol-Meyers Squibb, Daiichi Sankyo, Eli Lilly, Elsevier, Forest Labs, GlaxoSmithKline, Guidant Corporation, Johnson & Johnson, Merck, Pfizer, Proctor & Gamble, sanofi-aventis, Schering-Plough Corporation, Scios, Inc., and WebMD; grants from Amgen, AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, Bristol-Meyers Squibb, CardioKinetix, Inc., Cierra, Cordis, Edwards Lifesciences, Eli Lilly, GlaxoSmithKline, Guidant Corporation, Innocoll Pharmaceuticals, Johnson & Johnson, KCI Medical, Luitpoid Pharmaceutical, Medtronic, Merck, Momentum Pharmaceutical, Novartis, Portola Pharmaceutical, Pfizer, Pozen, Proctor & Gamble, Regado, sanofi-aventis, Schering-Plough Corporation, and The Medicines Company.

back to top

Seattle Genetics, Inc., Amgen, Inc., and Becton, Dickinson and Company

Moving Towards Personalized Medicine in Hematologic Malignancies

  • Peter van der Spek, PhD: indicated no conflicts of interest.
  • Malik Juweid, MD: indicated no conflicts of interest.
  • Volker Diehl, MD, PhD: consultant for Seattle Genetics DMC.
  • Andre Goy, MD: consultant for Millennium, Celgene Corporation, and Genentech, Inc.; non-CME services for Millennium, Celgene Corporation, and Genentech, Inc.
  • Rafael Fonseca, MD: consultant for Amgen, Inc., Bristol- Myers Squibb, Genzyme Corporation, Celgene Corporation, and Medtronic, Inc.; research support from Cylene Pharmaceuticals and Onyx Pharmaceuticals.
  • Martin S. Tallman, MD: advisory board for Genzyme Oncology.

back to top

Wallace H. Coulter Foundation

Improving Patient Care Through Innovations in Laboratory Medicine: Acute and Chronic Leukemia

  • Michael Borowitz, MD, PhD: consultant for Alexion Pharmaceuticals; research support from BD Biosciences and Genzyme.
  • Charles Caldwell, MD: indicated no conflicts of interest.
  • Andrew Rawstron, BSc, PhD: advisory board for Biogen Idec and Celgene; patents/royalties with BD Biosciences; honoraria/travel support from Roche.
  • Bharat Thyagarajan, MD: indicated no conflicts of interest.

back to top